VENCLEXTA (ven-KLEKS-tuh) is a prescription medicine that is approved to treat people with chronic lymphocytic leukemia (CLL) with 17p deletion, who have received at least one prior treatment. It is not known if VENCLEXTA is safe and effective in children. 

What is relapsed or refractory CLL?

Chronic lymphocytic leukemia, or CLL, is a blood cancer that affects your B cells, which may also be called B lymphocytes. B cells are a type of white blood cell that helps your body fight infection. When you have CLL, your abnormal B cells grow and build up in your blood and bone marrow. Over time, these cells can also accumulate in your lymph nodes, spleen, and liver.

Since you have already received at least one other therapy and your cancer either progressed or did not respond to CLL treatment, your doctor may use terms such as relapsed or refractory CLL.

Relapsed CLL and Refractory CLL Your treatment worked for a while but now your CLL has come back. Refractory CLL your CLL did not respond to the treatment you received or the cancer returned within 6 months of ending treatment image

What is 17p deletion?

17p deletion icon image

You may have heard the term 17p deletion from your doctor as a way to describe CLL. 17p deletion is a genetic change or mutation in which part of chromosome 17 is missing in some CLL cells. VENCLEXTA is approved for previously treated CLL patients with 17p deletion.

Ask your doctor if you have been tested for 17p deletion.

See additional information and support for VENCLEXTA